Occipital nerve stimulation

Last updated

Occipital nerve stimulation (ONS), also called peripheral nerve stimulation (PNS) of the occipital nerves, is used to treat chronic migraine patients who have failed to respond to pharmaceutical treatments.

Contents

The treatment involves the use of mild electrical impulses to stimulate the greater occipital nerve and lesser occipital nerve [1] which are part of the peripheral nervous system and are located at the back of the head just above the neck area.

The electrical impulses are generated by a small device called a neurostimulator – similar to an artificial cardiac pacemaker – which is implanted in the buttock, chest, low abdomen, beneath the shoulder blade or below the clavicle. [1] The electricity is delivered to the greater occipital nerve and lesser occipital nerve by small metal electrodes which are arranged on thin leads and implanted just under the skin. [2] The intensity of the electrical impulses can be adjusted using a small remote control device. [1]

History

The history of PNS is thoroughly reported by Slavin, 2011. [3] The use of PNS for chronic pain was first reported in 1967 by Wall and Sweet although the first implantations were performed in 1962 by Shelden. They demonstrated that electrical stimulation of peripheral nerves suppresses the perception of pain. A period of semi-experimental PNS usage continued for 15 – 20 years. During the latter half of the 1980s, PNS became an established surgical procedure. In the late 1990s, Weiner and Reed reported the percutaneous technique of inserting electrodes in the vicinity of the occipital nerves to treat occipital neuralgia. Weiner showed that placing a PNS electrode close to a nerve is effective for pain relief and a technically simple procedure. This pioneering work heralded the start of the modern era of PNS. It was 2003 before Popeney and Aló proposed using PNS for the treatment of chronic migraine. Subsequently, prospective randomized controlled trials were launched to gather additional clinical evidence.

This is further detailed in an article published by Cephalagia titled "Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study." [4]

In September 2011, St Jude Medical Inc. became the first company to receive European approval for the use of PNS in treating chronic migraine. [5]

Candidates for the therapy

Appropriate candidates for PNS of the occipital nerves for the treatment of chronic migraine must be diagnosed with chronic migraine which is classified as intractable.

Chronic migraine is defined by the International Headache Society (IHS) guidelines: [6]

Intractable chronic migraine is generally defined as chronic migraine with failure of three or more preventive drugs and at least moderate disability determined using a validated migraine disability instrument (e.g. MIDAS or HIT-6). [7]

Procedure

Pre-operation

Prior to the implantation, patients usually undergo a psychological assessment to assess their well-being and mental health. [1] The risks of the procedure will be discussed and the patient will be asked for their informed consent. [1] Risks that may be highlighted include no guarantee of effectiveness, infection, nerve damage, painful direct muscle stimulation, lead movement with loss of stimulation, lead fracture, battery failure, eventual need for battery replacement, hematoma and seroma formation. [1]

Implantation

In most cases, a trial (test) lead placement is performed in order to assess whether the stimulation will work as expected. [8] Local anesthetic is applied to the back of the neck and a Tuohy needle is advanced towards the location of the greater occipital nerve and lesser occipital nerve under fluoroscopic guidance. [8] [9] [10] When the location is confirmed, a temporary lead is placed through the needle before the needle is carefully removed. [8] [9] Electrical impulses are sent through the lead and its position is adjusted until the patient reports a "pins-and-needles" sensation, called paresthesia, across the areas of the nerves. [8] [9] If paresthesia is successfully achieved in the right place, permanent leads are usually implanted at a later date. [9] In some cases, the trial leads are left in for up to one week to see whether there is any relief of symptoms. [8]

Permanent lead placement may be carried out under general anesthetic [10] or local anesthetic with sedation. [8] First, a small incision is made at the base of the skull, then a Tuohy needle is advanced under fluoroscopic guidance towards the location of the greater occipital nerve and lesser occipital nerve on one side of the head. [8] [9] [10] When the lead is adequately positioned through the needle under fluoroscopic guidance, the needle is carefully removed and the lead is fixed in place. [8] [9] [10] Since most patients require two leads, a second lead is usually inserted and fixed in place on the other side of the head in the same way. [8] [10] The lead(s) are then tunneled to a neurostimulator device which is usually implanted the buttock, chest, low abdomen, beneath the shoulder blade or below the clavicle. [1]

Clinical evidence

Results from three randomized controlled trials have been published. One randomized controlled trial of 157 patients with chronic migraine was published in October 2012. [11] Participants were implanted with the device and then randomized to have the device turned on (the treatment group) or off (the control group) for 12 weeks. After week 12, participants received active treatment until week 52. All participants had trial stimulation to ensure correct position of electrodes. A total of 153 participants completed 12 weeks in the trial. There was a statistically significant difference (p<0.05) between the number of patients in the treatment group]and control group at the 30% reduction in pain level using the Visual Analogue Scale (VAS). In addition the study showed that, on average, the treatment group (device on) had 6.1 fewer days of headache days per month which was more than double the average reduction for the control group (device off), which is statistically significant (p<0.001). The clinical study investigators reported that the overall rate of serious device and procedure related adverse events was 1% and that these included one infection and one case of post-operative pain which required additional hospitalization.

In February 2011, the ONSTIM clinical study investigators reported three-month results from a randomized controlled trial of patients with chronic migraine. [12] Participants were first given occipital nerve block. Those who responded were randomized into three groups. The first group was a treatment group (33 participants) and received adjustable stimulation. The other two groups were control groups and received sham stimulation for one minute per day or standard medical management (17 participants each). Patients who achieved a 50% or greater reduction in their number of headache days per month or a three-point or greater reduction in average overall pain intensity compared with baseline were defined as responders to the therapy. 39% of patients in the adjustable stimulation group were responders, 6% in the sham stimulation group and 0% in the medical management group. The differences between the responder rates in the treatment group and control groups were statistically significant. Other outcome measures, such as number of headache days, were not statistically significantly different between the groups. However, the percentage reduction in headache days was 27% for the treatment group and less than 9% for each control group, showing a numerical advantage for the treatment group. No unanticipated device adverse events were reported. Movement of the lead occurred in 24% of subjects.

In December 2009, the PRISM study investigators reported three-month results in abstract form from a randomized controlled trial of 125 patients with chronic migraine. [13] [14] [15] Patients were randomized into two groups. One group was a treatment group and received active stimulation. The other was a control group and received sham stimulation. Patients in the treatment group reduced their number of migraine days per month by 5.5 from a baseline of 20.2 days per month. Patients in the control group reduced their number of migraine days per month by 3.9 from a baseline of 19.2 days per month. The difference between the two groups was not statistically significant.

Related Research Articles

<span class="mw-page-title-main">Migraine</span> Disorder resulting in recurrent moderate-severe headaches

Migraine is a common neurological disorder characterized by recurrent headaches. Typically, the associated headache affects one side of the head, is pulsating in nature, may be moderate to severe in intensity, and could last from a few hours to three days. Non-headache symptoms may include nausea, vomiting, and sensitivity to light, sound, or smell. The pain is generally made worse by physical activity during an attack, although regular physical exercise may prevent future attacks. Up to one-third of people affected have aura: typically, it is a short period of visual disturbance that signals that the headache will soon occur. Occasionally, aura can occur with little or no headache following, but not everyone has this symptom.

<span class="mw-page-title-main">Cluster headache</span> Neurological disorder

Cluster headache (CH) is a neurological disorder characterized by recurrent severe headaches on one side of the head, typically around the eye(s). There is often accompanying eye watering, nasal congestion, or swelling around the eye on the affected side. These symptoms typically last 15 minutes to 3 hours. Attacks often occur in clusters which typically last for weeks or months and occasionally more than a year.

<span class="mw-page-title-main">Transcutaneous electrical nerve stimulation</span> Therapeutic technique

Transcutaneous electrical nerve stimulation is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to reduce pain. The unit is usually connected to the skin using two or more electrodes which are typically conductive gel pads. A typical battery-operated TENS unit is able to modulate pulse width, frequency, and intensity. Generally, TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction or low frequency (<10 Hz) with an intensity that produces motor contraction. More recently, many TENS units use a mixed frequency mode which alleviates tolerance to repeated use. Intensity of stimulation should be strong but comfortable with greater intensities, regardless of frequency, producing the greatest analgesia. While the use of TENS has proved effective in clinical studies, there is controversy over which conditions the device should be used to treat.

Electroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain. There is evidence for some efficacy in treating moderate post-chemotherapy vomiting, but not for acute vomiting or delayed nausea severity.

Occipital neuralgia (ON) is a painful condition affecting the posterior head in the distributions of the greater occipital nerve (GON), lesser occipital nerve (LON), third occipital nerve (TON), or a combination of the three. It is paroxysmal, lasting from seconds to minutes, and often consists of lancinating pain that directly results from the pathology of one of these nerves. It is paramount that physicians understand the differential diagnosis for this condition and specific diagnostic criteria. There are multiple treatment modalities, several of which have well-established efficacy in treating this condition.

<span class="mw-page-title-main">Pterygopalatine ganglion</span>

The pterygopalatine ganglion is a parasympathetic ganglion found in the pterygopalatine fossa. It is largely innervated by the greater petrosal nerve ; and its postsinaptic axons project to the lacrimal glands and nasal mucosa. The flow of blood to the nasal mucosa, in particular the venous plexus of the conchae, is regulated by the pterygopalatine ganglion and heats or cools the air in the nose. It is one of four parasympathetic ganglia of the head and neck, the others being the submandibular ganglion, otic ganglion, and ciliary ganglion.

<span class="mw-page-title-main">Vagus nerve stimulation</span> Medical treatment that involves delivering electrical impulses to the vagus nerve.

Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression.

<span class="mw-page-title-main">Spinal cord stimulator</span> SCS TREATMENT

A spinal cord stimulator (SCS) or dorsal column stimulator (DCS) is a type of implantable neuromodulation device that is used to send electrical signals to select areas of the spinal cord for the treatment of certain pain conditions. SCS is a consideration for people who have a pain condition that has not responded to more conservative therapy. There are also spinal cord stimulators under research and development that could enable patients with spinal cord injury to walk again via epidural electrical stimulation (EES).

Hemicrania continua (HC) is a persistent unilateral headache that responds to indomethacin. It is usually unremitting, but rare cases of remission have been documented. Hemicrania continua is considered a primary headache disorder, meaning that it is not caused by another condition.

Migraine surgery is a surgical operation undertaken with the goal of reducing or preventing migraines. Migraine surgery most often refers to surgical decompression of one or several nerves in the head and neck which have been shown to trigger migraine symptoms in many migraine sufferers. Following the development of nerve decompression techniques for the relief of migraine pain in the year 2000, these procedures have been extensively studied and shown to be effective in appropriate candidates. The nerves that are most often addressed in migraine surgery are found outside of the skull, in the face and neck, and include the supra-orbital and supra-trochlear nerves in the forehead, the zygomaticotemporal nerve and auriculotemporal nerves in the temple region, and the greater occipital, lesser occipital, and third occipital nerves in the back of the neck. Nerve impingement in the nasal cavity has additionally been shown to be a trigger of migraine symptoms.

Electroanalgesia is a form of analgesia, or pain relief, that uses electricity to ease pain. Electrical devices can be internal or external, at the site of pain (local) or delocalized throughout the whole body. It works by interfering with the electric currents of pain signals, inhibiting them from reaching the brain and inducing a response; different from traditional analgesics, such as opiates which mimic natural endorphins and NSAIDs that help relieve inflammation and stop pain at the source. Electroanalgesia has a lower addictive potential and poses less health threats to the general public, but can cause serious health problems, even death, in people with other electrical devices such as pacemakers or internal hearing aids, or with heart problems.

Eugene G. Lipov, M.D. is a physician researcher and board-certified anesthesiologist who specializes in intervention-based pain management in the Chicago area.

Preventive treatment of migraine can be an important component of migraine management. Such treatments can take many forms, including everything from surgery, taking certain drugs or nutritional supplements, to lifestyle alterations such as increased exercise and avoidance of migraine triggers.

Multifocal motor neuropathy (MMN) is a progressively worsening condition where muscles in the extremities gradually weaken. The disorder, a pure motor neuropathy syndrome, is sometimes mistaken for amyotrophic lateral sclerosis (ALS) because of the similarity in the clinical picture, especially if muscle fasciculations are present. MMN is thought to be autoimmune. It was first described in the mid-1980s.

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR).

Migraine treatment may be either prophylactic (preventive) or abortive (rescue). Prevention is better than cure, so the ideal treatment goal is to prevent migraine attacks. Because migraine is an exceedingly complex condition, there are various preventive treatments which have their effect by disrupting different links in the chain of events that occur during a migraine attack. As rescue treatments also target and disrupt different processes occurring during migraine, these are summarized, with their relative merits and demerits.

Neuromodulation is "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". It is carried out to normalize – or modulate – nervous tissue function. Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli such as a magnetic field (rTMS), an electric current, or a drug instilled directly in the subdural space. Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), and by 2014, these had been at minimum demonstrated in mammalian models, or first-in-human data had been acquired. The most clinical experience has been with electrical stimulation.

A peripheral nerve interface is the bridge between the peripheral nervous system and a computer interface which serves as a bi‐directional information transducer recording and sending signals between the human body and a machine processor. Interfaces to the nervous system usually take the form of electrodes for stimulation and recording, though chemical stimulation and sensing are possible. Research in this area is focused on developing peripheral nerve interfaces for the restoration of function following disease or injury to minimize associated losses. Peripheral nerve interfaces also enable electrical stimulation and recording of the peripheral nervous system to study the form and function of the peripheral nervous system. For example, recent animal studies have demonstrated high accuracy in tracking physiological meaningful measures, like joint angle. Many researchers also focus in the area of neuroprosthesis, linking the human nervous system to bionics in order to mimic natural sensorimotor control and function. Successful implantation of peripheral nerve interfaces depend on a number of factors which include appropriate indication, perioperative testing, differentiated planning, and functional training. Typically microelectrode devices are implanted adjacent to, around or within the nerve trunk to establish contact with the peripheral nervous system. Different approaches may be used depending on the type of signal desired and attainable.

<span class="mw-page-title-main">Occipital nerve block</span>

Occipital nerve block is a procedure involving injection of steroids or anesthetics into regions of the greater occipital nerve and the lesser occipital nerve used to treat chronic headaches.

<span class="mw-page-title-main">Konstantin Slavin</span>

Konstantin Slavin is a Professor and Head of the Department of Stereotactic and functional neurosurgery at the University of Illinois College of Medicine. He is a former president of the American Society for Stereotactic and functional neurosurgery and current vice-president of the World Society for Stereotactic and Functional Neurosurgery. His specialties include Aneurysm, Brain surgery, Brain Tumor, Cerebrovascular Disorders, Craniotomy, Dystonia, Essential Tremor, Facial Nerve Pain, Facial Pain, Glioblastoma, Headache disorders, Laminectomy, Lower back pain, Movement Disorders, Multiple Sclerosis, Neck Pain, Neurosurgery, Neurosurgical Procedures, Pain, Parkinson Disease, Spinal Cord Injuries, and Stroke.

References

  1. 1 2 3 4 5 6 7 Trentman, Terrence L; Zimmerman RS; Dodick DW (2011). "Occipital Nerve Stimulation: Technical and Surgical Aspects of Implantation". Prog Neurol Surg. Progress in Neurological Surgery. 24: 96–108. doi:10.1159/000323043. ISBN   978-3-8055-9489-9. PMID   21422780.
  2. ↑ Slavin, Konstantin V. (2011). "Technical Aspects of Peripheral Nerve Stimulation: Hardware and Complications". Prog Neurol Surg. Progress in Neurological Surgery. 24: 189–202. doi:10.1159/000323275. ISBN   978-3-8055-9489-9. PMID   21422789.
  3. ↑ Slavin, Konstantin V. (2011). "History of peripheral nerve stimulation". Prog Neurol Surg. Progress in Neurological Surgery. 24: 1–15. doi:10.1159/000323002. ISBN   978-3-8055-9489-9. PMID   21422772.
  4. ↑ "Reed Migraine Article on Safety and efficacy of peripheral nerve stimulation of the occipital nerves" (PDF). Cephalagia. Retrieved 12 November 2012.
  5. ↑ "St Jude Press release". St. Jude Medical Inc. Archived from the original on 5 January 2013. Retrieved 8 August 2012.
  6. ↑ "The International Classification of Headache Disorders, 2nd Edition, 1st revision (May, 2005)". Archived from the original on 2013-04-13. Retrieved 2012-08-08.
  7. ↑ Silberstein, Stephen D.; Dodick DW; Pearlman S (2010). "Defining the pharmacologically intractable headache for clinical trials and clinical practice". Headache. 50 (9): 1499–506. doi:10.1111/j.1526-4610.2010.01764.x. PMID   20958296. S2CID   12400426.
  8. 1 2 3 4 5 6 7 8 9 AIó, Kenneth M.; Abramova MV; Richter EO (2011). "Percutaneous Peripheral Nerve Stimulation". Prog Neurol Surg. Progress in Neurological Surgery. 24: 41–S7. doi:10.1159/000323023. ISBN   978-3-8055-9489-9. PMID   21422775.
  9. 1 2 3 4 5 6 Ellens, Damien J.; Levy RM (2011). "Peripheral Neuromodulation for Migraine Headache". Prog Neurol Surg. Progress in Neurological Surgery. 24: 109–117. doi:10.1159/000323890. ISBN   978-3-8055-9489-9. PMID   21422781.
  10. 1 2 3 4 5 Trentman, Terrence L.; Slavin KV; Freeman JA; Zimmerman RS (2010). "Occipital Nerve Stimulator Placement via a Retromastoid to Infraclavicular Approach: A Technical Report". Stereotact Funct Neurosurg. 88 (2): 121–125. doi:10.1159/000289356. PMID   20197713. S2CID   38409120.
  11. ↑ Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, Reed K, Narouze S, Mogilner A, Goldstein J, Trentman T, Vaisman J, Vaisma J, Ordia J, Weber P, Deer T, Levy R, Diaz RL, Washburn SN, Mekhail N (Dec 2012). "Safety and Efficacy of Peripheral Nerve Stimulation of the Occipital Nerves for the Management of Chronic Migraine: Results from a Randomized, Multicenter, Double-blinded, Controlled Study". Cephalalgia. 32 (16): 1165–1179]. doi:10.1177/0333102412462642. PMID   23034698. S2CID   2467841.
  12. ↑ Saper, Joel R.; Dodick DW; Silberstein SD; McCarville S; Sun M; Goadsby PJ (2011). "Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study". Cephalalgia. 31 (3): 271–85. doi:10.1177/0333102410381142. PMC   3057439 . PMID   20861241.
  13. ↑ Lipton, Richard B.; Goadsby PJ; Cady RK; Aurora SK; Grosberg BM; Freitag FG; Silberstein SD; Whiten DM; Jaax KN (2010). "PRISM study: Occipital nerve stimulation for treatment-refractory migraine". Headache. 50 (3): 509–519. doi:10.1111/j.1526-4610.2010.01615.x. PMID   20456145. S2CID   28468605.
  14. ↑ "Abstracts for the 14th Congress of the International Headache Conference, Philadelphia, USA, 10 - 13 September 2009".
  15. ↑ Diener, Hans-Christoph; Dodick DW; Goadsby PJ; Lipton RB; Olesen J (2012). "Chronic migraine—classification, characteristics and treatment". Nature Reviews Neurology. 8 (3): 162–171. doi:10.1038/nrneurol.2012.13. PMID   22331030. S2CID   7858323.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.